Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
0–85
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male and/or female patients below 85 years of age (inclusive)
Diagnosis of mild Alzheimer's Disease
Mini-Mental State Examination (MMSE) 20 to 26 (inclusive) at screening, untreated or on stable dose of cholinesterase inhibitor or memantine over the last 4 weeks prior to clinical assessments
You may not be if
Previously participated in an AD vaccine study and received active treatment
History or presence of an active autoimmune disease
History or presence of seizure disorder
Presence of significant coronary heart disease and/or cerebrovascular disease
Presence of other neurodegenerative disease and/or psychiatric disorders (with the exception of successfully treated depression)
Advanced, severe, progressive or unstable disease that might interfere with the safety, tolerability and pharmacodynamic assessments of the patient
Clareo Health | Safety, Tolerability and Abeta-specific Antibody Response of Repeated i.m. Injections of Adjuvanted CAD106 in Mild Alzheimer Patients
